These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16039122)

  • 41. Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.
    Kopka IE; Young DN; Lin LS; Mumford RA; Magriotis PA; MacCoss M; Mills SG; Van Riper G; McCauley E; Egger LE; Kidambi U; Schmidt JA; Lyons K; Stearns R; Vincent S; Colletti A; Wang Z; Tong S; Wang J; Zheng S; Owens K; Levorse D; Hagmann WK
    Bioorg Med Chem Lett; 2002 Feb; 12(4):637-40. PubMed ID: 11844689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.
    Boys ML; Schretzman LA; Chandrakumar NS; Tollefson MB; Mohler SB; Downs VL; Penning TD; Russell MA; Wendt JA; Chen BB; Stenmark HG; Wu H; Spangler DP; Clare M; Desai BN; Khanna IK; Nguyen MN; Duffin T; Engleman VW; Finn MB; Freeman SK; Hanneke ML; Keene JL; Klover JA; Nickols GA; Nickols MA; Steininger CN; Westlin M; Westlin W; Yu YX; Wang Y; Dalton CR; Norring SA
    Bioorg Med Chem Lett; 2006 Feb; 16(4):839-44. PubMed ID: 16298127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.
    Gong Y; Barbay JK; Dyatkin AB; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Ballentine SA; Hageman WE; Masucci JA; Maryanoff BE; Damiano BP; Andrade-Gordon P; Hlasta DJ; Hornby PJ; He W
    J Med Chem; 2006 Jun; 49(11):3402-11. PubMed ID: 16722660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.
    Palmer JT; Hirschbein BL; Cheung H; McCarter J; Janc JW; Yu ZW; Wesolowski G
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2909-14. PubMed ID: 16546382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.
    Yang GX; Chang LL; Truong Q; Doherty GA; Magriotis PA; de Laszlo SE; Li B; MacCoss M; Kidambi U; Egger LA; McCauley E; Van Riper G; Mumford RA; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1497-500. PubMed ID: 12031328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists.
    Lin LS; Kopka IE; Mumford RA; Magriotis PA; Lanza T; Durette PL; Kamenecka T; Young DN; de Laszlo SE; McCauley E; Riper GV; Kidambi U; Egger LA; Tong X; Lyons K; Vincent S; Stearns R; Colletti A; Teffera Y; Fenyk-Melody J; Schmidt JA; MacCoss M; Hagmann WK
    Bioorg Med Chem Lett; 2002 Feb; 12(4):611-4. PubMed ID: 11844683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. N-Cycloalkanoyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.
    Sidduri A; Tilley JW; Hull K; Lou JP; Kaplan G; Sheffron A; Chen L; Campbell R; Guthrie R; Huang TN; Huby N; Rowan K; Schwinge V; Renzetti LM
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2475-8. PubMed ID: 12161161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.
    Lin LS; Lanza T; Jewell JP; Liu P; Jones C; Kieczykowski GR; Treonze K; Si Q; Manior S; Koo G; Tong X; Wang J; Schuelke A; Pivnichny J; Wang R; Raab C; Vincent S; Davies P; Maccoss M; Mumford RA; Hagmann WK
    J Med Chem; 2009 Jun; 52(11):3449-52. PubMed ID: 19441819
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.
    Xu J; Wei L; Mathvink RJ; Edmondson SD; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5373-7. PubMed ID: 16919457
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New GABA-modulating 1,2,4-oxadiazole derivatives and their anticonvulsant activity.
    Lankau HJ; Unverferth K; Grunwald C; Hartenhauer H; Heinecke K; Bernöster K; Dost R; Egerland U; Rundfeldt C
    Eur J Med Chem; 2007 Jun; 42(6):873-9. PubMed ID: 17303289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
    Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
    J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a.
    Skinner PJ; Cherrier MC; Webb PJ; Shin YJ; Gharbaoui T; Lindstrom A; Hong V; Tamura SY; Dang HT; Pride CC; Chen R; Richman JG; Connolly DT; Semple G
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5620-3. PubMed ID: 17804224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
    Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ligand binding of leukocyte integrin very late antigen-4 involves exposure of sulfhydryl groups and is subject to redox modulation.
    Liu SY; Tsai MY; Chuang KP; Huang YF; Shieh CC
    Eur J Immunol; 2008 Feb; 38(2):410-23. PubMed ID: 18196516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and structure-activity relationships of C-glycosylated oxadiazoles as inhibitors of glycogen phosphorylase.
    Tóth M; Kun S; Bokor E; Benltifa M; Tallec G; Vidal S; Docsa T; Gergely P; Somsák L; Praly JP
    Bioorg Med Chem; 2009 Jul; 17(13):4773-85. PubMed ID: 19450985
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigation of the teratogenic potential of VLA-4 antagonist derivatives in rats.
    Sakurai K; Matsuoka T; Suzuki C; Kinoshita J; Takayama G; Shimomura K
    Reprod Toxicol; 2014 Nov; 49():162-70. PubMed ID: 25194688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of unique VLA-4 antagonists from a combinatorial library.
    de Laszlo SE; Li B; McCauley E; Van Riper G; Hagmann WK
    Bioorg Med Chem Lett; 2002 Feb; 12(4):685-8. PubMed ID: 11844701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
    Rydzewski RM; Burrill L; Mendonca R; Palmer JT; Rice M; Tahilramani R; Bass KE; Leung L; Gjerstad E; Janc JW; Pan L
    J Med Chem; 2006 May; 49(10):2953-68. PubMed ID: 16686537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The identification and optimization of orally efficacious, small molecule VLA-4 antagonists.
    Huryn DM; Konradi AW; Ashwell S; Freedman SB; Lombardo LJ; Pleiss MA; Thorsett ED; Yednock T; Kennedy JD
    Curr Top Med Chem; 2004; 4(14):1473-84. PubMed ID: 15544538
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and anticancer activities of novel 3,5-disubstituted-1,2,4-oxadiazoles.
    Kumar D; Patel G; Johnson EO; Shah K
    Bioorg Med Chem Lett; 2009 May; 19(10):2739-41. PubMed ID: 19376704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.